UPDATE: Oppenheimer Maintains Outperform On HealthEquity, Lowers Target To $76 As Firm Notes 'Standalone HQY Continues to Track Well; But Lack of Visibility Around WAGE Will be an Overhang'
Benzinga_Newsdesk